QIAGEN N.V. (QGEN) recently announced two significant achievements in sustainability, recognized by My Green Lab — a non-profit organization dedicated to advancing sustainability in scientific research. The company earned the prestigious ACT (Accountability, Consistency, and Transparency) Environmental Impact Factor Label for the new QIAwave products and achieved My Green Lab Platinum certification for its Sample technologies R&D lab in Germany.These recognitions underscore QIAGEN’s commitment to sustainabi ...

Qiagen N.V. (NYSE:QGEN) Q4 2023 Earnings Conference Call February 7, 2024 9:00 AM ET Company Participants John Gilardi - VP, Corporate Communications & IR Thierry Bernard - Chief Executive Officer Roland Sackers - Chief Financial Officer Conference Call Participants Derik De Bruin - Bank of America Odysseas Manesiotis - Berenberg Casey Woodring - JPMorgan Aisyah Noor - Morgan Stanley Douglas Schenkel - Wolfe Research Falko Friedrichs - Deutsche Bank Matthew Sykes - Goldman Sachs Operator Good day. I'm Melin ...

QIAGEN N.V.’s (QGEN) fourth-quarter 2023 adjusted earnings per share (EPS) were 55 cents (same at a constant exchange rate or CER), up 3.8% from the prior-year period. However, the figure missed the Zacks Consensus Estimate by 1.8%.The adjustment excludes the impact of certain non-recurring items like business integration, acquisition and restructuring-related expenses, purchased intangible amortization expenses and non-cash interest expense charges, among others.The GAAP EPS for the quarter was 42 cents, u ...

Qiagen (QGEN) reported $509.16 million in revenue for the quarter ended December 2023, representing a year-over-year increase of 2.3%. EPS of $0.55 for the same period compares to $0.55 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $504.16 million, representing a surprise of +0.99%. The company delivered an EPS surprise of -1.79%, with the consensus EPS estimate being $0.56.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and h ...

QIAGEN N.V. (QGEN) recently announced a collaboration with Penn State University, United States, to create a shared research and education facility for fast-developing microbiome sciences. The company will provide instruments and kits for preparing and processing microbial samples for the flagship project at Penn State’s Huck Institutes of the Life Sciences, “One Health Microbiome Center”, to support faculty and students.The latest development will significantly boost the company’s Life Sciences business ar ...

Germantown, Maryland, and State College, Pennsylvania, Jan. 25, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA))) today announced a first-in-kind collaboration with Penn State University in the United States to create a shared research and education facility for the fast-developing microbiome sciences. The university-industry partnership will serve as a beacon for this field by investigating research opportunities that address challenges and research gaps facing the microbiome, w ...

Venlo, the Netherlands, Jan. 18, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA))) today announced details for completion of the synthetic share repurchase plan to return up to approximately $300 million that combines a direct capital repayment to QIAGEN shareholders with a reverse stock split. The repayment from existing cash reserves is expected to lead to an approximately 3% reduction in the number of issued shares (based on current share price). The terms of the syntheti ...

QIAGEN N.V. (QGEN) recently received FDA clearance for the NeuMoDx CT/NG Assay 2.0, growing its test menu for its integrated PCR-based clinical molecular testing systems NeuMoDx 96 and 288 in the United States. The Assay is designed to improve accessibility, affordability and timeliness in sexually transmitted infection (STI) testing in the country. The latest development will significantly boost the company’s Molecular Diagnostics business.About QIAGEN’s PCR-Based Clinical Molecular Testing SystemsThe NeuM ...

Venlo, The Netherlands, Jan. 11, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the fourth quarter and full year 2023. Press release date/time: Tuesday, February 6, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date/time: Wednesday, February 7, at 15:00 Frankfurt time / 14:00 London time / 09:00 New York time.  Three options for joining the conference call Register for call back connect ...

QIAGEN’s (QGEN) business is expected to get a boost from its expanded test menu and growth-driving strategic collaborations. However, overdependence on relationships with collaborative partners and foreign exchange headwinds are major downsides. The stock carries a Zacks Rank #3 (Hold) currently.QIAGEN’s long-term business strategy involves entering into strategic alliances as well as marketing and distribution arrangements with academic, corporate and other partners relating to the development, commerciali ...